Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 12/2007

01.12.2007

Esophagectomy for High Grade Dysplasia is Safe, Curative, and Results in Good Alimentary Outcome

verfasst von: Valerie A. Williams, Thomas J. Watson, Fernando A. Herbella, Oliver Gellersen, Daniel Raymond, Carolyn Jones, Jeffrey H. Peters

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The increasing adoption of endoscopic therapies and expectant surveillance for patients with high grade dysplasia (HGD) in Barrett’s esophagus has created considerable controversy regarding the ideal treatment choice. Confusion may be due, in part, to a limited understanding of the outcomes associated with surgical resection for HGD and extrapolation of data derived from patients undergoing an esophagectomy for invasive cancer. The purpose of our study was to document the perioperative and symptomatic outcomes and long-term survival after esophagectomy for HGD of the esophagus.

Material and Methods

The study population consisted of 38 patients who underwent esophagectomy for biopsy-proven HGD between 10/1999 and 6/2005. Three patients were excluded from analysis due to obvious tumor on upper endoscopy. Patients were evaluated regarding ten different foregut symptoms and administered a ten-question appraisal of eating and bowel habits. Outcome measures included postoperative morbidity and mortality, the prevalence of invasive cancer in the esophagectomy specimens, symptomatic and functional alimentary results, patient satisfaction, and long-term survival. Median follow-up was 32 months (range, 7–83).

Results

Thirty-day postoperative and in-hospital mortality was zero. Complications occurred in 37% (13/35), and median length of stay was 10 days. Occult adenocarcinoma was found in 29% (10/35) of surgical specimens (intramucosal in four; submucosal in five; and intramuscular in one with a single positive lymph node.) Patients consumed a median of three meals per day, most (76%, 26/34) had no dietary restrictions, and two-thirds (23/34) considered their eating pattern to be normal or only mildly impacted. Meal size, however, was reported to be smaller in the majority (79%, 27/34) of patients. Median body mass index (BMI) decreased slightly after surgery (28.6 vs 26.6, p > 0.05), but no patient’s BMI went below normal. The number of bowel movements/day was unchanged or less in a majority (82%) of patients after surgery. Fifteen of 34 (44%) patients reported loose bowel movements, which occurred less often than once per week in 10 of the 15. One patient had symptoms of dumping. Mean symptom severity scores improved for all symptoms except dysphagia and choking. Four patients developed foregut symptoms that occurred daily. Most patients (82%) required at least one postoperative dilation for dysphagia. Almost all (97%) patients were satisfied. Disease-free survival was 100%, and overall survival was 97% (34/35) at a median of 32 months.

Conclusion

Esophagectomy is an effective and curative treatment for HGD and can be performed with no mortality, acceptable morbidity, and good alimentary outcome. These data provide a gold standard for comparison to alternative therapies.
Literatur
2.
3.
Zurück zum Zitat Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249–1256.PubMed Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249–1256.PubMed
4.
Zurück zum Zitat Spechler SJ. The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. J Clin Gastroenterol. 2003;36(5 Suppl):S2–S5. (discussion S26–S28).PubMedCrossRef Spechler SJ. The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. J Clin Gastroenterol. 2003;36(5 Suppl):S2–S5. (discussion S26–S28).PubMedCrossRef
5.
Zurück zum Zitat Ormsby AH, Petras RE, Henricks WH, Rice TW, Rybicki LA, Richter JE, Goldblum JR. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002;51:671–676.PubMedCrossRef Ormsby AH, Petras RE, Henricks WH, Rice TW, Rybicki LA, Richter JE, Goldblum JR. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002;51:671–676.PubMedCrossRef
6.
Zurück zum Zitat Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol.. 2001;32(4):368–378.PubMedCrossRef Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol.. 2001;32(4):368–378.PubMedCrossRef
7.
Zurück zum Zitat Skinner DB, Walther BC, Riddell RH, et al. Barrett’s esophagus: Comparison of benign and malignant cases. Ann Surg. 1983;198:554–566.PubMedCrossRef Skinner DB, Walther BC, Riddell RH, et al. Barrett’s esophagus: Comparison of benign and malignant cases. Ann Surg. 1983;198:554–566.PubMedCrossRef
8.
Zurück zum Zitat Schmidt HG, Riddell RD, Walther B, et al. Dysplasia in Barrett’s esophagus. J Cancer Res Clin Oncol. 1985;110:145–152.PubMedCrossRef Schmidt HG, Riddell RD, Walther B, et al. Dysplasia in Barrett’s esophagus. J Cancer Res Clin Oncol. 1985;110:145–152.PubMedCrossRef
9.
Zurück zum Zitat Lee RG. Dysplasia in Barrett’s esophagus: A clinicopathologic study of six patients. Am J Surg Pathol. 1985. 845–852. Lee RG. Dysplasia in Barrett’s esophagus: A clinicopathologic study of six patients. Am J Surg Pathol. 1985. 845–852.
10.
Zurück zum Zitat Hamilton SR, Smith RL. The relationship between columnar epithelial dysplasia and invasive carcinoma arising in Barrett’s esophagus. Am J Clin Pathol. 1987;87:301–312.PubMed Hamilton SR, Smith RL. The relationship between columnar epithelial dysplasia and invasive carcinoma arising in Barrett’s esophagus. Am J Clin Pathol. 1987;87:301–312.PubMed
11.
Zurück zum Zitat Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1998;94:81–90. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1998;94:81–90.
12.
Zurück zum Zitat DeMeester TR, Attwood SE, Smyrk TC, Therkildsen DH, Hinder RA. Surgical therapy in Barrett’s esophagus. Ann Surg. 1990;212(4):528–540.PubMedCrossRef DeMeester TR, Attwood SE, Smyrk TC, Therkildsen DH, Hinder RA. Surgical therapy in Barrett’s esophagus. Ann Surg. 1990;212(4):528–540.PubMedCrossRef
13.
Zurück zum Zitat Altorki NK, Sunagaawa M, Little AG, et al. High-grade dysplasia in the columnar-lined esophagus. Am J Surg. 1991;161:97–100.PubMedCrossRef Altorki NK, Sunagaawa M, Little AG, et al. High-grade dysplasia in the columnar-lined esophagus. Am J Surg. 1991;161:97–100.PubMedCrossRef
14.
Zurück zum Zitat McArdle JE, Lewin KJ, Randall G, et al. Distribution of dysplasia and early invasive carcinoma in Barrett’s esophagus. Hum Pathol. 1992;23:479–482.PubMedCrossRef McArdle JE, Lewin KJ, Randall G, et al. Distribution of dysplasia and early invasive carcinoma in Barrett’s esophagus. Hum Pathol. 1992;23:479–482.PubMedCrossRef
15.
Zurück zum Zitat Pera M, Trastek VF, Carpenter HA, et al. Barrett’s esophagus with high-grade dysplasia: An indication for esophagectomy. Ann Thorac Surg. 1999;54:204. Pera M, Trastek VF, Carpenter HA, et al. Barrett’s esophagus with high-grade dysplasia: An indication for esophagectomy. Ann Thorac Surg. 1999;54:204.
16.
Zurück zum Zitat Levine DS, Haggett RC, Blout PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.PubMed Levine DS, Haggett RC, Blout PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.PubMed
17.
Zurück zum Zitat Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett’s esophagus: does it help? J Thorac Cardiovasc Surg. 1993;105(3):383–388.PubMed Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett’s esophagus: does it help? J Thorac Cardiovasc Surg. 1993;105(3):383–388.PubMed
18.
Zurück zum Zitat Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett’s esophagus: Long-term results of a prospective study. Br J Surg. 1996;83:274–227.PubMedCrossRef Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett’s esophagus: Long-term results of a prospective study. Br J Surg. 1996;83:274–227.PubMedCrossRef
19.
Zurück zum Zitat Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108(5):813–822.PubMed Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108(5):813–822.PubMed
20.
Zurück zum Zitat Edwards MJ, Gable DR, Lentsch AB, et al. The rationale for esophagectomy as the optimal therapy for Barrett’s esophagus with high-grade dysplasia. Ann Surg. 1996;223:585–591.PubMedCrossRef Edwards MJ, Gable DR, Lentsch AB, et al. The rationale for esophagectomy as the optimal therapy for Barrett’s esophagus with high-grade dysplasia. Ann Surg. 1996;223:585–591.PubMedCrossRef
21.
Zurück zum Zitat Ferguson MK, Naunheim KS. Resection for Barrett’s mucosa with high-grade dysplasia: Implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg. 1997;114:824–829.PubMedCrossRef Ferguson MK, Naunheim KS. Resection for Barrett’s mucosa with high-grade dysplasia: Implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg. 1997;114:824–829.PubMedCrossRef
22.
Zurück zum Zitat Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study. Am J Gastroenterol. 1997;92:586–591.PubMed Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study. Am J Gastroenterol. 1997;92:586–591.PubMed
23.
Zurück zum Zitat Patti MG, Arcerito M, Feo CV, Worth S, De Pinto M, Gibbs VC, Gantert VC, Tyrrell D, Ferrell LF, Way LW. Barrett’s esophagus: a surgical disease. J Gastrointest Surg. 1999;3(4):397–403.PubMedCrossRef Patti MG, Arcerito M, Feo CV, Worth S, De Pinto M, Gibbs VC, Gantert VC, Tyrrell D, Ferrell LF, Way LW. Barrett’s esophagus: a surgical disease. J Gastrointest Surg. 1999;3(4):397–403.PubMedCrossRef
24.
Zurück zum Zitat Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: Extent of disease and implications for effective therapy. Ann Surg. 1990;230:433–444.CrossRef Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: Extent of disease and implications for effective therapy. Ann Surg. 1990;230:433–444.CrossRef
25.
Zurück zum Zitat Nguyen NT, Schauer P, Luketich JD. Minimally invasive esophagectomy for Barrett’s esophagus with high-grade dysplasia. Surgery. 2000;127:284–290.PubMedCrossRef Nguyen NT, Schauer P, Luketich JD. Minimally invasive esophagectomy for Barrett’s esophagus with high-grade dysplasia. Surgery. 2000;127:284–290.PubMedCrossRef
26.
Zurück zum Zitat Zaninotto G, Parenti AR, Ruol A, et al. Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus. Br J Surg. 2000;87:1102–1105.PubMedCrossRef Zaninotto G, Parenti AR, Ruol A, et al. Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus. Br J Surg. 2000;87:1102–1105.PubMedCrossRef
27.
Zurück zum Zitat Headrick JR, Nichols FC, Miller DL, Allen MS, Trastek VF, Deschamps C, Schleck CD, Thompson AM, Pairolero PC. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73(6):1697–1703.PubMedCrossRef Headrick JR, Nichols FC, Miller DL, Allen MS, Trastek VF, Deschamps C, Schleck CD, Thompson AM, Pairolero PC. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73(6):1697–1703.PubMedCrossRef
28.
Zurück zum Zitat Romagnoli R, Collard JM, Gutschow C, Yamusah N, Salizzoni M. Outcomes of dysplasia arising in Barrett’s esophagus: a dynamic view. J Am Coll Surg. 2003;197:365–371.PubMedCrossRef Romagnoli R, Collard JM, Gutschow C, Yamusah N, Salizzoni M. Outcomes of dysplasia arising in Barrett’s esophagus: a dynamic view. J Am Coll Surg. 2003;197:365–371.PubMedCrossRef
29.
Zurück zum Zitat Tseng EE, Wu TT, Yeo CJ, Heitmiller RF. Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome - an update. J Gastrointest Surg. 2003;7(2):164–170.PubMedCrossRef Tseng EE, Wu TT, Yeo CJ, Heitmiller RF. Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome - an update. J Gastrointest Surg. 2003;7(2):164–170.PubMedCrossRef
30.
Zurück zum Zitat Reed MF, Tolis G, Edil BH, Allan JS, Donahue DM, Gaissert HA, Moncure AC, Wain JC, Wright CD, Mathisen DJ. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg. 2005;79:1110–1115.PubMedCrossRef Reed MF, Tolis G, Edil BH, Allan JS, Donahue DM, Gaissert HA, Moncure AC, Wain JC, Wright CD, Mathisen DJ. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg. 2005;79:1110–1115.PubMedCrossRef
31.
Zurück zum Zitat Sujendran V, Sica G, Warren B, Maynard N. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett’s oesophagus. Eur J Cardiothorac Surg. 2005;28:763–766.PubMedCrossRef Sujendran V, Sica G, Warren B, Maynard N. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett’s oesophagus. Eur J Cardiothorac Surg. 2005;28:763–766.PubMedCrossRef
32.
Zurück zum Zitat Moraca RJ, Low DE. Outcomes and health-related quality of life after esophagectomy for high-grade dysplasia and intramucosal cancer. Arch Surg. 2006;141:545–551.PubMedCrossRef Moraca RJ, Low DE. Outcomes and health-related quality of life after esophagectomy for high-grade dysplasia and intramucosal cancer. Arch Surg. 2006;141:545–551.PubMedCrossRef
33.
Zurück zum Zitat Rice TW. Esophagectomy is the treatment of choice for high-grade dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2006;101:2177–2184.PubMedCrossRef Rice TW. Esophagectomy is the treatment of choice for high-grade dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2006;101:2177–2184.PubMedCrossRef
34.
Zurück zum Zitat Chang LC, Oelschlager BK, Quiroga E, Parra JD, Mulligan M, Wood DE, Pellegrini CA. Long-term outcome for high-grade dysplasia or cancer found during surveillance for Barrett’s esophagus. J Gastrointest Surg. 2006;10:341–346.PubMedCrossRef Chang LC, Oelschlager BK, Quiroga E, Parra JD, Mulligan M, Wood DE, Pellegrini CA. Long-term outcome for high-grade dysplasia or cancer found during surveillance for Barrett’s esophagus. J Gastrointest Surg. 2006;10:341–346.PubMedCrossRef
35.
Zurück zum Zitat Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381–390.PubMedCrossRef Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381–390.PubMedCrossRef
36.
Zurück zum Zitat Bailey SH, Bull DA, Harpole DH, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75:217–222.PubMedCrossRef Bailey SH, Bull DA, Harpole DH, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75:217–222.PubMedCrossRef
37.
Zurück zum Zitat Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Eng J Med. 2002;346(15):1128–1137.CrossRef Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Eng J Med. 2002;346(15):1128–1137.CrossRef
38.
Zurück zum Zitat Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918–1925.PubMedCrossRef Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918–1925.PubMedCrossRef
39.
Zurück zum Zitat Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236(2):177–183.PubMedCrossRef Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236(2):177–183.PubMedCrossRef
40.
Zurück zum Zitat Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, DeMeeser TR. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202(4):588–596.PubMedCrossRef Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, DeMeeser TR. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202(4):588–596.PubMedCrossRef
41.
Zurück zum Zitat Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;3477:1662–1669.CrossRef Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;3477:1662–1669.CrossRef
42.
Zurück zum Zitat Schnell TG, Sontag SL, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120(7):1607–1619.PubMedCrossRef Schnell TG, Sontag SL, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120(7):1607–1619.PubMedCrossRef
43.
Zurück zum Zitat Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004;99(9):1657–1666.PubMedCrossRef Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004;99(9):1657–1666.PubMedCrossRef
44.
Zurück zum Zitat Oh DS, Hagen JA, Chandrasoma PT, et al. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg. 2006;203:152–161.PubMedCrossRef Oh DS, Hagen JA, Chandrasoma PT, et al. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg. 2006;203:152–161.PubMedCrossRef
45.
Zurück zum Zitat Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630–1639.PubMedCrossRef Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630–1639.PubMedCrossRef
Metadaten
Titel
Esophagectomy for High Grade Dysplasia is Safe, Curative, and Results in Good Alimentary Outcome
verfasst von
Valerie A. Williams
Thomas J. Watson
Fernando A. Herbella
Oliver Gellersen
Daniel Raymond
Carolyn Jones
Jeffrey H. Peters
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 12/2007
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-007-0330-9

Weitere Artikel der Ausgabe 12/2007

Journal of Gastrointestinal Surgery 12/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.